MOUNTAIN VIEW, Calif.
SanBio, Inc., a leader in regenerative cell therapies for neurological disorders, joins the Smithsonian Institution in recognizing Stanford University’s Dr. Gary Steinberg, chair of neurosurgery, for his pioneering research in the treatment of stroke patients. Steinberg received the Smithsonian’s prestigious American Ingenuity Award in Life Sciences for his unrelenting and unconventional approach to helping stroke patients regain motor function. Steinberg was the primary investigator in SanBio’s Phase 1/2a clinical trial in which stroke patients receiving SB623 demonstrated clinically significant improvement in motor function.
Said Dr. Damien Bates, Chief Medical Officer and Head of Research at SanBio, “This well-deserved recognition of Dr. Steinberg’s exemplary career and ongoing research shines light on the potential of stem cell therapies like SB623 to treat patients suffering from chronic physical impairments following a stroke.”
Dr. Steinberg was honored in the Life Sciences category for his commitment to neurological research and stroke patients. He also received recognition in Smithsonian magazine.
About SanBio, Inc. (SanBio)
SanBio is a regenerative medicine company headquartered in Tokyo, Japan, and Mountain View, California, with cell-based products in various stages of research, development, and clinical trials. Its proprietary cell-based product, SB623, is currently in a Phase 2b clinical trial for treatment of chronic motor impairments resulting from stroke with its joint development partner, Sumitomo Dainippon Pharma Co., Ltd., in the United States and Canada. SanBio is also implementing a global Phase 2 clinical trial in the United States and Japan using SB623 for treatment of motor impairment resulting from traumatic brain injury. More information about SanBio, Inc. is available at http://sanbio.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180104005262/en/
CONTACT
For SanBio, Inc.
Kris Patrow, 612-455-1748
Kris.Patrow@PadillaCo.com
